Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids

International Journal of Laboratory Hematology

Volumn 29, Issue 2, 2007, Pages 132-138

  Lu, X G ^a   Mao, J S ^a   Tong, J F ^a   Zhu, L ^a   Liu, J ^a   Gong, X B ^a   Huang, J ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Plasmin; Plasminogen; Pleural and ascitic fluid; Tissue plasminogen activator; Urokinase plaminogen activator receptor; Urokinase plasminogen activator

Indexed keywords

ALPHA 2 ANTIPLASMIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR; BLOOD CLOTTING FACTOR;

ADULT; AGED; ARTICLE; ASCITES FLUID; CLINICAL ARTICLE; COLORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; MALE; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PLEURA EFFUSION; PRIORITY JOURNAL; TUBERCULOUS PLEURISY; ADOLESCENT; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; NEOPLASM; PLEURA CAVITY; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; BLOOD COAGULATION FACTORS; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEOPLASMS; PLEURAL CAVITY; TUBERCULOSIS;

EID: 34249742466     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2006.00835.x     Document Type: Article

References (14)

1. Abe J., Urano T., Konno H., Erhan Y., Tanaka T., Nishino N., Takada A. Nakamura S. (1999) Large and more invasive colorectal carcinoma contains large amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 86, 2602 2611.
2. Buo L., Karlsrud T.S., Dyrhaug G., Bell H., Engstrom L., Johansen H.T. Aasen A.O. (1995) The fibrinolytic system in human ascities. Scandinavian Journal of Gastroenterology 30, 1101 1107.
3. Casslen B., Bossmar T., Lencander I. Astedt B. (1994) Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. European Journal of Cancer 30A, 1302 1309.
4. Hellehrekers B.W., Emeis J.J., Kooistra T., Trimbos J.B., Moore N.R., Zwinderman K.H. Trimbos-Kemper T.C. (2005) A role for the fibrinolytic system in postsurgical adhension formation. Fertility and Sterility 83, 122 129.
5. Hua C.C., Chang L.C., Chen Y.C. Chang S.C. (1999) Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions. Chest 116, 1292 1296.
6. Kwak S.M., Park C.S., Cho J.S., Ryu J.S. Kim S.K. (2004) The effects of urokinase instillation therapy via percutaneous transthoracic catheter in loculated tuberculous pleural effusion: a randomized prospective study. Yonsei Medical Journal 45, 822 828.
7. Lijnen H.R. (2000) Molecular interactions between the plasminogen/plasmin and matrix metllproteinase systems. Fibrinolysis Proteolysis 14, 175 178.
8. Lu X.G., Chen Z.S., Ye Z.Y. Wang Z.S. (1985) The significance of examination with fibrinogen degradation product of pleural fluid. Chinese Journal of Tuberculosis and Respiratory Diseases 8, 310.
9. Lu X.G., Chen Z.S., Ye Z.Y. Wang Z.S. (1987) The significance about fibrinogen degradation product and examination of fibrinolytic activity. Chinese Journal of Internal Medicine 9, 530 532.
10. Ozdemir O., Emn S., Karakoca Y., Sayinalp N., Akay H., Dundar S. Baris I. (1996) Fibrinolytic system plasma and pleural fluid in malignant pleural mesothelioma. Thrombosis Research 84, 121 128.
11. Philip J.E., Aless M.C., Philip J.C., Aillaud M., Barriere J.R., Arnaud A. Juhan V.I. (1995) Fibrinolytic and inflammatory processes in pleural effusions. European Respiratory Journal 8, 1352 1356.
12. Svanberg L. Astedt B. (1975) Coagulative and fibrinolytic properties of ascitic fluid associated with ovarian tumors. Cancer 35, 1382 1384.
13. Toschi V., Rocchini G.M., Motta A., Fiorini G.F., Cimminiello C., Violi F., Castelli C., Sironi D. Gibelli A. (1993) The hyperfibrinolytic state of hepatocirrhosis: possible pathogenetic role of ascites. Biomedicine and Pharmacotherapy 47, 345 352.
14. Whawell S.A., Scott-Coombes D.M., Vipond M.N., Tebbutt S.J. Thompson J. (1994) Tumor necrosis factor-mediated release of plasminogen activator inhibitor 1 by human peritoneal mesothelial cells. British Journal of Surgery 81, 214 216.